457 related articles for article (PubMed ID: 33177176)
1. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
3. Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells.
Song L; Ye W; Cui Y; Lu J; Zhang Y; Ding N; Hu W; Pei H; Yue Z; Zhou G
Oncotarget; 2017 May; 8(19):31977-31992. PubMed ID: 28404888
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
[TBL] [Abstract][Full Text] [Related]
5. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features.
Takamatsu D; Kiyozawa D; Kohashi K; Kinoshita F; Toda Y; Ishihara S; Eto M; Oda Y
Pathol Res Pract; 2023 Apr; 244():154423. PubMed ID: 36989848
[TBL] [Abstract][Full Text] [Related]
8. Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.
Wang X; Zhang T; Song Z; Li L; Zhang X; Liu J; Liu X; Qiu L; Qian Z; Zhou S; Feng L; Hu G; Meng B; Zhai Q; Ren X; Fu K; Li L; Wang P; Zhang H
Int J Cancer; 2019 Sep; 145(5):1414-1422. PubMed ID: 30664812
[TBL] [Abstract][Full Text] [Related]
9. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
10. Detailed analysis of adenosine A2a receptor (
Vogt TJ; Gevensleben H; Dietrich J; Kristiansen G; Bootz F; Landsberg J; Goltz D; Dietrich D
Oncoimmunology; 2018; 7(8):e1452579. PubMed ID: 30221045
[No Abstract] [Full Text] [Related]
11. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
12. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
13. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
15. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.
Kordaß T; Osen W; Eichmüller SB
Front Immunol; 2018; 9():813. PubMed ID: 29720980
[TBL] [Abstract][Full Text] [Related]
16. Complex regulation of ecto-5'-nucleotidase/CD73 and A
Nedeljkovic N
Pharmacol Res; 2019 Jun; 144():99-115. PubMed ID: 30954629
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma.
Liu Y; Gou X; Wei Z; Yu H; Zhou X; Li X
Aging (Albany NY); 2020 Jul; 12(15):15359-15373. PubMed ID: 32716909
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
20. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
